How well do routine molecular diagnostics detect rifampicin heteroresistance in *Mycobacterium tuberculosis*?

Kamela C. S. Ng, Philip Supply, Frank G. J. Cobelens, Cyril Gaudin, Julian Gonzalez-Martin, Bouke C. de Jong, Leen Rigouts

*Mycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam UMC location Academic Medical center, Amsterdam, The Netherlands; Genoscreen, 1 Rue du Professeur Calmette, 59000 Lille, France; Servei de Microbiologia, Centre de Diagnòstic Biomèdic, Hospital Clínic, Institut de Salut Global de Barcelona, Universitat de Barcelona, Spain; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium*

Running Head: Routine detection of rifampicin heteroresistance

#Corresponding author, Mycobacteriology Unit, Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerpen, Belgium; Email: kng@itg.be; Phone: +32(0)33455345; Fax number: +32(0)32476333
ABSTRACT

Rifampicin heteroresistance – where rifampicin-resistant and -susceptible tuberculosis bacilli co-exist – may result in failed standard TB treatment and potential spread of rifampicin-resistant strains. Detection of rifampicin heteroresistance in routine rapid diagnostic tests (RDTs) allows for patients to receive prompt and effective multidrug-resistant-TB treatment, and may improve rifampicin-resistant TB control.

The limit of detection (LOD) of rifampicin heteroresistance for phenotypic drug susceptibility testing by the proportion method is 1%, yet is insufficiently documented for RDTs. We therefore aimed to determine, for the four RDTs (XpertMTB/RIF, XpertMTB/RIF Ultra, GenotypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII), the LOD per probe and mutation, validated by colony-forming-unit-counting and targeted deep sequencing (Deeplex-MycTB).

We selected one rifampicin-susceptible and four rifampicin-resistant strains, with mutation D435V, H445D, H445Y, and S450L respectively, mixed them in various proportions in triplicate, tested them with each RDT, and determined the LODs per mutation type. Deeplex-MycTB revealed concordant proportions of the minority resistant variants in the mixtures. The Deeplex-MycTB-validated-LODs ranged from 20-80% for XpertMTB/RIF, 20-70% for Xpert Ultra, 5-10% for GenotypeMTBDRplusv2.0, and 1-10% for GenoscholarNTM+MTBI for the different mutations.

Deeplex-MycTB, GenotypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII, provide explicit information on rifampicin heteroresistance for the most frequently detected mutations. Classic Xpert and Ultra report rifampicin heteroresistance as rifampicin resistance, while Ultra may denote rifampicin heteroresistance through ‘mixed patterns’ of wild-type and mutant melt probe melt peak temperatures.
Overall, our findings inform end-users that the threshold for reporting resistance in case of rifampicin heteroresistance is the highest for Classic Xpert and Ultra, to resolve phenotypic and genotypic discordant rifampicin-resistant TB results.
INTRODUCTION

Resistance to rifampicin (RIF) – the most potent anti-TB drug – is a major barrier to tuberculosis (TB) control. In 2017, 71% of global RIF resistant-TB (RR-TB) cases were not diagnosed (1). The diagnosis of RR-TB may be complicated by RIF heteroresistance, observed in patient samples where RR and RIF-susceptible (RS) strains co-exist (2, 3), which may be missed and diagnosed as RS because of detection limits. RIF heteroresistance may arise from an existing resistant clonal subpopulation or from a mixed infection of independent strains with RR and RS profiles. Such heteroresistance, also known as ‘unfixed’ resistance, precedes full blown resistance (‘fixed’ resistance, 100% RR) as a result of further resistance selection under treatment (3-6). Failure to detect these minority resistant variants can thus result in unsuccessful treatment and potential spread of RR-TB strains (2, 3, 7).

The World Health Organization currently endorses use of rapid diagnostic tests (RDTs) for timely detection of RR-TB strains: XpertMTB/RIF (classic Xpert), Xpert Ultra (Ultra), and the Line Probe Assays (LPAs) GenotypeMTBDRplusv2.0 (LPA-Hain) and Genoscholar NTM+MDRTBII (LPA-Nipro) (8-10). Among these RDTs, only the LPAs are currently known to explicitly detect RIF heteroresistance in case of mixtures with mutations covered by the assay, exemplified by both wild-type and mutant bands being present, also known as ‘mixed patterns’ (3, 11).

In this study, we define RIF heteroresistance limit of detection (LOD) as the minimum proportion of mutant bacilli in a total mycobacterial population present in a sample, needed for RIF resistance to be detected (3). It is known that phenotypic drug susceptibility testing by the proportion method determines at least 1% resistant subpopulation in clinical samples (3, 12, 13). In the abovementioned RDTs however, the RIF heteroresistance LOD in association with the specific \textit{rpoB} mutation, is insufficiently documented. In the case of
classic Xpert, previous studies report LOD values ranging from 65 to 100% (14, 15), for Ultra, the first validation study conducted by the manufacturer presented LODs only for mutations L430P, H445N (20-40%), and S450L (5-10%) (16), whereas LODs of Genoscholar NTM+MDRTB II have not been reported yet.

High coverage depths achieved through pre-selected amplified genes allow targeted deep sequencing to capture and quantify minority resistant variants of *Mycobacterium tuberculosis* mutants and detect RIF heteroresistance with high sensitivity (17, 18). As an example of such an approach, Deeplex®-MycTB (Genoscreen, France; Deeplex) employs ultra-deep sequencing of a single, 24-plexed amplicon mix to detect drug resistance-associated mutations in *M. tuberculosis* complex (MTBC) strains, in addition to mycobacterial species identification and MTBC strain genotyping, with a 24-48 turnaround time starting from smear positive clinical samples or primary cultures. Among the 18 main gene targets associated with 1st and 2nd–line drug resistance included in Deeplex-MycTB, the *rpoB* gene – associated with RR - is covered by two amplicons of which one comprises the main mutation hotspot region also known as the rifampicin resistance determining region (RRDR) (19).

Precise documentation of LODs for most relevant *rpoB* mutations and for the state-of-the-art RDTs is necessary for timely and more accurate identification of RIF heteroresistance and prompt initiation of appropriate treatment. Therefore, we determined the LODs of classic Xpert, Ultra, LPA-Hain, and LPA-Nipro for detecting RIF heteroresistance linked with RR mutations S450L, D435V, H445D, and H445Y, in relation with the different probes used in each RDT. These four mutations are most frequently detected in association with RR-TB in the global MTBC strain population according to large-scale studies (20, 21). We used simulated mixtures of selected, cultured RR and RS-TB strains, at ratios initially based on
colony-forming-unit (CFU) counts after McFarland standardization of the bacillary suspensions. Targeted deep sequencing by Deeplex-MycTB was used as reference for quantitative assessment of the RR:RS ratios.

**MATERIALS AND METHODS**

**Selection of strains**

We selected one RS- and four RR- *M. tuberculosis* strains from the Belgian Coordinated Collection of Microorganisms hosted in the Institute of Tropical Medicine Antwerp (22), on the basis of the presence of mutations confirmed by Sanger sequencing and captured by mutation probes of LPA-Hain and LPA-Nipro: the Beijing 2.2.1.1 strains TB-TDR-0090 (ITM-041208 with *rpoB* mutation S450L (S531L in *E. coli* numbering)) and TB-TDR-0100 (ITM-041220, D435V (D516V)); the LAM 4.3.4.2 strains TB-TDR-0036 (ITM-000930, H445D (H526D)) and TB-TDR-0131 (ITM-041289, H445Y (H526Y)) (23). The RS strain was the Euro-American lineage 4.9 TDR-0140 (ITM-091634, *rpoB* wildtype).

**Bacillary suspensions and baseline colony-forming-unit (CFU) counting**

We prepared two batches of McFarland standard 1 suspensions for each RR and the RS strain, and performed serial dilution until $10^{-4}$-$10^{-6}$. The first batch was tested by classic Xpert, LPA-Hain, and LPA-Nipro, and the second batch was prepared to be assessed by Ultra, which was only released after initial testing. To check if numbers of bacilli were similar among the cultures after McFarland standardization, we performed CFU counting by spread plating (Figure S1 a). From each dilution, 100µl was plated in triplicate on Dubos agar plates that were sealed with a double layer of parafilm, placed in ziplock bags and incubated at 37°C for four weeks, before colony counting.

**Simulation of RIF heteroresistance**
RIF heteroresistance was simulated for each mutation type, by mixing RS and respective RR strains in triplicate in the following proportions (R:S): 0:100, 1:99, 5:95, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, and 100:0 (Figure S1 b), and vortexing the mixtures for 20 seconds. Replicate 3 of each RR:RS mixture per batch was tested by targeted deep sequencing (Deeplex-MycTB), the results of which served for cross-validation of variant quantification.

Subjection of RR:RS mixtures to RDTs

We subjected mixtures of the RR-TB bacillary suspensions to classic Xpert and Ultra (9, 10), and thermolysates to LPA-Hain and LPA-Nipro following manufacturer’s instructions. We recorded the LODs and corresponding RDT probe reaction per mutation type, in comparison with values cross-validated by CFU counts and variant quantification with Deeplex-MycTB. First reading of the LPA strips was done by the person who prepared the mixtures and performed the tests, while second reading was done by a colleague who was blinded to the sample information to ensure objective reading of raw results. Additionally, for LPA-Nipro, the Genoscholar Reader - a mobile application developed by Nipro (Osaka, Japan, https://itunes.apple.com/by/app/genoscholar-reader/id1149733183?mt=8) was utilized. In their standard reporting, Classic Xpert and Ultra (Supplemental File Figure S4 a) report RIF heteroresistance, above or equal its LOD, as RR. Users can indirectly infer RIF heteroresistance from Ultra data, as shown by the simultaneous presence of wild-type and mutant (Mut) melt peak temperatures at the ‘Melt Peaks’ tab (Supplemental File Figure S4 b). When generating the results in portable document format, users must tick the ‘Melt Peaks’ box to include the melt peak temperatures associated with each wild-type and Mut melt probe, which may denote RIF heteroresistance, in the extended report (Supplemental File Figure S4 b). Full resistance is detected by presence of both rpoB4A and rpoB3 Mut melt
probes for mutation S450L, whereas RIF heteroresistance is detected only by the rpoB4A
Mut melt probe in combination with the corresponding wild-type melt probe (Figure 1).

Quantitative assessment of mutant proportions by Deeplex-MycTB

Per batch, we quantitatively assessed proportions of resistant subpopulations in replicate 3
of the prepared RR:RS mixtures by Deeplex-MycTB. These proportions were determined by
calculating the mean percentages of minority resistant variants across all mutation positions
borne by each of the RR strains in the rpoB gene and other gene targets depending on the
strain genetic background.

Thermolysates of the RR:RS mixtures prepared as previously described (24) were subjected
to amplicon deep sequencing, using Deeplex-MycTB Kits for the amplification according to
the manufacturer’s instructions. Replicates 3 of all first batch mixtures were tested with the
classical 18-gene target version, while replicate 3 of the second batch with S450L-WT
mixtures was tested with a customized version, including 5 gene targets (rpoB, katG, inhA,
fabG1, gyrA). Amplicons were purified using Agencourt® AMPure® XP magnetic beads
(Beckman Coulter, USA) and quantified by fluorescence quantification in 96-well plates on
Victor. Paired-end libraries of 150-bp read length were prepared using the Nextera XT DNA
Sample Preparation kit (Illumina Inc., San Diego, 160 CA, USA) and sequenced on Illumina
MiniSeq using standard procedures. Variant calling was performed using a dedicated,
parameterized web application developed by Genoscreen. The nominal threshold for calling
minority resistant variants – indicating heteroresistance for drug resistance associated
mutations – is set at a minimum of 3% of all reads, after filtering and depending on the
coverage depths, to minimize false positive calls due to background technical noise (19, 25,
26). Variants present in lower proportions than 3% in the relevant rpoB mutation positions
were detected separately from the web application,(27) without application of this nominal threshold in the analysis pipeline.

RESULTS

After McFarland standardization of the different strain cultures, the mean CFU counts for dilutions $10^{-4}$-$10^{-6}$ of the three replicates of both first and second batches of the different RS and RR bacillary suspensions were very similar (Table S1 a and b). The proportions obtained from the Deeplex-MycTB analysis were overall consistent with the expected mixture ratios and the relative variation seen among CFU counts, as relative deviations from expected values were limited to 0-16% (Table 1, Figure S2).

We excluded replicate 3 from the first batch of S450L-WT preparation due to substantially high deviation across all mixture ratios, as revealed by Deeplex-MycTB (Supplemental Figure S3). This deviation potentially reflects pipetting variation or bacillary clumping despite similar CFU counts of the respective RR and RS strains. Hence for the S450L-WT mixture, replicate 3 of batch 2 – which was initially only tested by Ultra and Deeplex – was subjected also to classic Xpert and the LPAs, given the good correlation between the two batches and to ensure triplicate testing for all mixtures.

In line with these levels of experimental variation, all rpoB variants from 5:95 RR:RS mixtures were called by the Deeplex application in proportions ranging from 4.3% (H445Y) to 7.5% (H445D)(Table 1). When the analysis pipeline was used without applying this threshold, expected variants of 1:99 mixtures were also detected in percentages ranging from 1.0% (H445Y) to 1.6% (D435V), which were above background levels of 0.0 to 0.05% detected in the 0:100 mixtures (i.e. wild type strain only) on these specific sequence positions. The average minimum coverage depth observed from the Deeplex analyses was 1595 reads.
Among the available classical RDTs, LPAs had a lower LOD to detect RIF heteroresistance compared to classic Xpert and Ultra. The proportion of variants required to be detectable through LPA-Hain was 5% for mutation S450L and 5-10% for mutations D435V, H445D, and H445Y (Table S2). LPA-Nipro performed similarly, with 1-5%, 5%, 5-10% and 10% resistant bacilli detected for mutations S450L, H445D, D435V, and H445Y respectively (Table S2). LPA reading results were consistent between the two readers. Additionally, the ‘automated’ Genoscholar reader had similar results with manual reading for mutations H445Y and S450L; whereas it had lower sensitivity for mutations D435V (20% Genoscholar reader vs 5% manual reading) and H445D (10% Genoscholar reader vs 5% manual reading) (Table S3, Figure S5 a-d).

In contrast, Classic Xpert detected mutation S450L only in mixtures with at least 20-40% resistant bacilli, mutation H445D with at least 40-60% and mutations D435V and H445Y with at least 70-80% mutant bacilli (Table S2). Likewise, Ultra required a minimum of 20-30% resistant bacilli to detect mutation S450L, 40-50% for D435V, 40-60% for H445D and 60-70% for H445Y (Table S2; Figure 1).

Notably, in case of S450L at 20% mutant bacilli, only Ultra rpoB4 Mut melt A probe was observed, whereas both rpoB4 Mut melt A and rpoB3 Mut melt probes were present in case of 100% S450L (Figure 1). For mutations D435V, H445D, and H445Y only one Mut melt probe was observed, whether hetero- or fully resistant. The melt peak temperatures did not differ among hetero- or fully resistant populations for all four mutations tested (Figure 1).

**DISCUSSION**

We found that the LPAs detect rifampicin heteroresistance better than classic Xpert and Xpert Ultra. The LODs we documented differ by capturing RDT probe and mutation type. We
inform end-users that in contrast with classic Xpert, Xpert Ultra may denote rifampicin heteroresistance through ‘mixed patterns’ of wild-type and mutant melt probe melt peak temperatures.

Xpert employs an automated heminested real-time polymerase chain reaction assay in which short overlapping probes bind to the rifampicin resistance-determining region of the wild-type *M. tuberculosis* rpoB gene (14, 28). The line probe assays on the other hand rely on multiplex amplification and reverse hybridization involving both wild-type and mutant probes on a membrane strip (29). The observed differences in LODs can be linked to the inherent detecting mechanisms of these RDTs.

As seen from the analysis of the different heteroresistant mixtures defined based on bacterial colony counts, Deeplex-MycTB provided useful information for validating qualitative observations from the RDTs.

The LPA-Hain LOD documented in this study was consistent with a previous study which employed version 1 of the LPA-Hain kit (3). Further, the initial visual reading of LPA results was consistent with results of second blinded reading and Genoscholar Reader, although we observed that the mobile application was less sensitive than visual reading for mutations D435V and H445D.

The LODs recorded for classic Xpert and Ultra were higher (less sensitive) than for the LPAs. As a foremost example, classic Xpert performed relatively poorly in detecting heteroresistant mixtures with mutation S450L, which is by far the globally most prevalent allele in RR-TB (9, 21). Nevertheless, the 20-40% LOD we found for classic Xpert was lower (more sensitive) compared to previous studies which recorded 65-90% LOD (14, 15). Ultra performed similarly to classic Xpert in detecting minority resistant variants of mutations S450L and H445D, but did relatively better in capturing those of mutations D435V and H445Y (Table 2).
The 20% Ultra LOD for S450L was slightly less sensitive than the 5-10% LOD reported for the same mutation by Chakravorty and colleagues (16), who tested single mixtures of RR and RS DNA. We observed higher (less sensitive) LODs for the non-S450L mutations, consistent with findings of Chakravorty et al. (16).

Apart from the slight differences in the LODs recorded for classic Xpert and Ultra, we observed that Ultra allows users to infer from raw results on the computer screen – under ‘Melt Peaks’ tab – the phenomenon of heteroresistance (Supplemental File Figure S4 b, Figure 1), which is not possible from classic Xpert data. RIF heteroresistance may be rapidly detected by Ultra through observed melt peak temperatures of both wild-type and Mut melt probes akin to mixed patterns of absent wild-type and developed mutant bands in LPA.

Further, in a sample with S450L mutation, observing only the melt peak temperature of rpoB4 Mut melt A probe (vs rpoB4 Mut melt A and rpoB3 Mut melt probes for 100% RR) and corresponding wild-type melt probe may also denote RIF heteroresistance (Figure 1).

This information is deemed useful for conducting research on Ultra data and could be practical in the field if export of the melt peak temperatures through the LIS port becomes feasible in future software updates, together with other raw data (e.g. wild-type and Mut melt probes associated with RR mutation). Export to connectivity solutions such as DataToCare (Savics, Belgium), GXAlert (SystemOne, USA), or C360 (Cepheid, USA), with possible integration into e-Health patient charts beyond tuberculosis diagnostics, allows to transform this data into usable information for the National TB Programs using a combination of unique patient ID and geographical information (9, 30). This may not only greatly benefit the remote resolution of discordant results to improve patient management, but also aids to build more systematic data on the prevalence and impact of heteroresistance on a programmatic level.
Our study has limitations. We performed LPA testing of thermolysates in order to allow ‘optimal’ reading of results. Routine LPA is commonly done directly on clinical specimens, where background hybridization is more common and can be harder to distinguish from heteroresistance, as both phenomena may produce faint(er) bands which are often disregarded. Thus, the sensitivity for heretoresistance detection that we determined for the LPAs likely represent the upper bound of values achievable in clinical practice. Moreover, LPA will not detect heteroresistance for mutations not covered by a mutant probe. We addressed potential variability resulting from bacillary clumping and pipetting by inclusion of biological replicates, showing differences in LOD of maximum two dilutions amongst replicates with the same mutation.

In conclusion, we report distinct abilities of LPA-Hain, LPA-Nipro, classic Xpert, and Ultra to detect the most common RR-conferring mutations in varying mutant proportions against quantitative results of Deeplex-MycTB. We found that the LPAs have more sensitive LODs than Ultra, although they detect heteroresistance only for the four most common undisputed mutations – D435V, H445D, H445Y, and S450L. For mutations without confirmatory mutant (MUT) band, such as L452P, RIF heteroresistance cannot be detected, and with faint intensity of the WT band (29), it may be difficult to distinguish between WT and (hetero)resistance. Ultra on the other hand, can detect RR and RIF heteroresistance associated with all rpoB mutations within the hotspot, albeit requiring a higher proportion of mutant bacilli than LPA. The LPAs and Deeplex-MycTB provide direct information on the occurrence of RIF heteroresistance, whereas Ultra, after informing that RR was detected, may suggest RIF heteroresistance only through additional examination of wild-type and Mut melt probes and corresponding melt peak temperatures in the raw data on the computer screen or in the generated extended report (Supplemental File Figure S4 b).
The clinical importance of heteroresistance is likely substantial (2), akin to ‘fixed’, i.e. 100% resistance. The proportion method for phenotypic drug susceptibility testing, which has been around for over half a century, by design, tests for ≥1% resistant subpopulations (3, 12, 13), with strong predictive value for poor treatment outcome, at least for the core drugs, e.g. fluoroquinolones (31) and rifampicin (3). Moreover, samples with ≥5% minority gyrA resistant variants were found to have the same minimum inhibitory concentration level as that of samples with 100% fluoroquinolone resistance (L. Rigouts, submitted for publication, (31)), while for rpoB, the Mycobacterium Growth Indicator Tube phenotypic drug susceptibility testing results were similar for samples with ≥5% minority resistant variants and 100% RIF resistance (3). Taken together, this implicates that in samples with resistant subpopulations of at least 5%, classification of heteroresistance as ‘RR’, even when less sensitive than the proportion method, is probably key, notwithstanding the lack of direct evidence on clinical impact. Our findings can thus inform and guide TB reference laboratory staff, healthcare providers, and researchers, that the threshold for reporting resistance in case of rifampicin heteroresistance is the highest for Classic Xpert and Ultra, to resolve phenotypic and genotypic discordant rifampicin-resistant TB results. Prospective large-scale clinical studies using next generation sequencing approaches (2, 7) are necessary to establish the proportion of mutants that predicts poor outcome of treatment with the specific drug.

ACKNOWLEDGEMENTS

We thank the Belgian Coordinated Collections of Microorganisms in the Institute of Tropical Medicine Antwerp (http://bccm.belspo.be/about-us/bccm itm) for the strains tested in this study; and Siemon Gabriëls, Michèle Driesen, Wim Mulders, Jelle Keysers, and Pauline Lempens of the Institute of Tropical Medicine Antwerp Mycobacteriology Unit, and
Stéphanie Duthoy and Gaëlle Bisch of Genoscreen for their contribution in the experiments and data analysis.

K.C.S.N. was supported by Erasmus Mundus Joint Doctorate Fellowship grant 2016-1346, and B.d.J. and L.R by an ERC starting grant INTERRUPTB (311725). The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

Philip Supply was a consultant of Genoscreen.

REFERENCES

1. Organization WH. 2017. Global Tuberculosis Report 2017.
2. Ley SD, de Vos M, Van Rie A, Warren RM. 2019. Deciphering Within-Host Microevolution of Mycobacterium tuberculosis through Whole-Genome Sequencing: the Phenotypic Impact and Way Forward. Microbiol Mol Biol Rev 83.
3. Folkvardsen DB, Thomsen VO, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E. 2013. Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol 51:4220-2.
4. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33:368-74.
5. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, Matthys F. 1999. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 3:451-3.
6. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ, Study CTG. 2011. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 305:1415-23.
7. Metcalfe JZ, Streicher E, Theron G, Colman RE, Allender C, Lemmer D, Warren R, Engeltalher DM. 2017. Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance. Am J Respir Crit Care Med 196:1191-1201.
8. Pai M, Nicol MP, Boehme CC. 2016. Tuberculosis Diagnostics: State of the Art and Future Directions. Microbiol Spectr 4.
9. Ng KC, Meehan CJ, Torrea G, Goeminne L, Diels M, Rigouts L, de Jong BC, Andre E. 2018. Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results. JMI Med Inform 6:e12.
10. Ng KCS, van Deun A, Meehan CJ, Torrea G, Driesen M, Gabriels S, Rigouts L, Andre E, de Jong BC. 2018. Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations. J Clin Microbiol 56.
11. Tolani MP, D’Souza DT, Mistry NF. 2012. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 12:9.

12. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41:21-43.

13. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. 1963. Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ 29:565-78.

14. Blakemore R, Storey E, Helb D, Kop J, Banada P, Owens MR, Chakravorty S, Jones M, Alland D. 2010. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48:2495-501.

15. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, Collman PG, Klausner JD, Modongo C. 2014. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 52:2429-22.

16. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Galla A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvdze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. 2017. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. MBio 8.

17. Operario DJ, Koeppel AF, Turner BD, Bao Y, Pholwat S, Banu S, Foongladda S, Mpagama S, Gratz J, Ogarkov O, Zhadova S, Heysell SK, Houp ER. 2017. Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis. PLoS One 12:e0175622.

18. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. 2014. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 58:3270-5.

19. Makhado NA, Matabane E, Facchin M, Pincon C, Jouet A, Boutachkourt F, Goeminne L, Gaudin C, Maphalala G, Beckert P, Niemann S, Delvenne JC, Delmee M, Razwiedani L, Nchabeleng M, Supply P, de Jong BC, Andre E. 2018. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis doi:10.1016/S1473-3099(18)30496-1.

20. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniowski FA, Allix-Beguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA, Modernizing Medical Microbiology Informatics G. 2015. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15:1193-1202.

21. Coll F, Phelan J, Hill-Cawthorne GA, Nair MB, Mallard K, Ali S, Abdallah AM, Alghamdi S, Alsomali M, Ahmed AO, Portelli S, Oppong Y, Alves A, Bessa TB, Campino S, Caws M, Chatterjee A, Crampin AC, Dheda K, Furnham N, Glynn JR, Grandjean L, Minh Ha D, Hasan R, Hasan Z, Hibberd ML, Joloba M, Jones-Lopez EC, Matsumoto T, Miranda A, Moore DJ, Mocillo N, Panaiaov S, Parkhill J, Pencha A, Perdigao J, Portugal I, Rchid Z, Robledo J, Sheen P, Shesha NT, Sirgel FA, Sola C, Oliveira Sousa E, Streicher EM, Helden PV, Viveiros M, Warren RM, McNerney R, Pain A, et al. 2018. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet 50:307-316.

22. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. 2012. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis 16:24-31.
23. Coll F, McNerney R, Guerra-Assuncao JA, Glynn JR, Perdigao J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. 2014. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun 5:4812.

24. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A. 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 51:2641-5.

25. Tagliani E, Hassan MO, Waberi Y, De Filippo MR, Falzon D, Dean A, Zignol M, Supply P, Abdoulkader MA, Hassangue H, Cirillo DM. 2017. Culture and Next-generation sequencing-based drug susceptibility testing unveil high levels of drug-resistant-TB in Djibouti: results from the first national survey. Sci Rep 7:17672.

26. El Achkar S, Demanche C, Osman M, Rafei R, Ismail MB, Yaacoub H, Pincon C, Duthoy S, De Matos F, Gaudin C, Trovato A, Cirillo DM, Hamze M, Supply P. 2019. Drug-Resistant Tuberculosis, Lebanon, 2016 - 2017. Emerg Infect Dis 25:564-568.

27. Kohl TA, Utpatel C, Schleusener V, De Filippo MR, Beckert P, Cirillo DM, Niemann S. 2018. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ 6:e5895.

28. Lawn SD, Nicol MP. 2011. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 6:1067-82.

29. HainLifeScience. 2015. GenoType MTBDRplus VER 2.0 Molecular Genetic Assay for Identification of the M. tuberculosis Complex and its Resistance to Rifampicin and Isoniazid from Clinical Specimens and Cultivated Samples.

30. Andre E, Isaacs C, Affolabi D, Alagna R, Brockmann D, de Jong BC, Cambau E, Churchyard G, Cohen T, Delmee M, Delvenne JC, Farhat M, Habib A, Holme P, Keshavjee S, Khan A, Lightfoot P, Moore D, Moreno Y, Mundade Y, Pai M, Patel S, Nyaruhirira AU, Rocha LE, Takle J, Trebucq A, Creswell J, Boehme C. 2016. Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Int J Tuberc Lung Dis 20:999-1003.

31. Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A. 2016. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J Antimicrob Chemother 71:314-23.
Tables

Table 1. Proportions of minority resistant variants detected among the rifampicin-resistant:rifampicin-susceptible mixtures by targeted deep sequencing (Deeplex-MycTB).
The values represent the percentage of sequence reads bearing the indicated \textit{rpoB} mutation. Gray boxes represent proportions below the nominal threshold of 3% for calling minority resistant variants used in the Deeplex-MycTB application.

| RR:RS proportions | Minority resistant variant proportion detected for each specific mutation by Deeplex-MycTB |
|-------------------|-----------------------------------------------|
|                   | TB-TDR-0036 | TB-TDR-0090 | TB-TDR-0100 | TB-TDR-0131 |
| 0:100             | 0.03        | 0.05        | 0.0         | 0.03        |
| 1:99              | 1.3         | 1.3         | 1.6         | 1.0         |
| 5:95              | 7.5         | 5.0         | 6.0         | 4.3         |
| 10:90             | 14.7        | 10.0        | 10.0        | 8.7         |
| 20:80             | 28.6        | 21.7        | 25.2        | 20.8        |
| 30:70             | 39.9        | 28.4        | 35.4        | 26.0        |
| 40:60             | 55.9        | 41.6        | 43.6        | 37.9        |
| 50:50             | 60.0        | 50.1        | 60.6        | 46.0        |
| 60:40             | 69.4        | 61.9        | 67.0        | 57.5        |
| 70:30             | 77.6        | 64.9        | 69.6        | 66.7        |
| 80:20             | 85.5        | 69.8        | 86.2        | 79.0        |
| 100:0             | 98.3        | 99.9        | 98.3        | 98.9        |
Table 2. (Range of) limits of detection for rifampicin heteroresistance among triplicates, tested by different rapid diagnostic tests, per mutation type, with quantification of the respective lowest proportion by targeted deep sequencing (Deeplex-MycTB).

| Strain ID   | Rifampicin resistance-conferring mutation | LPA-Hain | Deeplex | LPA-Nipro | Deeplex | Xpert | Ultra | Deeplex |
|-------------|------------------------------------------|----------|---------|-----------|---------|-------|-------|---------|
|             |                                          | %LOD\(^1\) | %QP\(^{1,b}\) | %LOD\(^1\) | %QP\(^{1,b}\) | %LOD\(^1\) | %QP\(^{1,b}\) | %LOD\(^2\) | %QP\(^{2,b}\) |
| TB-TDR-0036 | H445D*                                   | 5-10     | 7.5     | 5         | 7.5     | 40-60 | 55.9  | 40-60   |
| TB-TDR-0090 | S450L*                                   | 5        | 5       | 1-5       | 5       | 20-40 | 21.7  | 20-30   | 21.7     |
| TB-TDR-0100 | D435V*                                   | 5-10     | 6       | 5-10      | 6       | 70-80 | 69.6  | 40-50   |
| TB-TDR-0131 | H445Y*                                   | 5-10     | 4.3     | 10        | 8.7     | 70-80 | 66.7  | 60-70   |

*in *M. tuberculosis* numbering; ^in E.coli numbering; Deeplex-MycTB = targeted deep sequencing; RDTs rapid diagnostic tests; LPA-Hain = Genotype MTDBRplus v2.0; LPA-Nipro = Genoscholar NTM + MTB II; Xpert = classic Xpert MTB/RIF; Ultra = Xpert MTB/RIF Ultra; \(^1\) = batch 1; \(^2\) = batch 2; \(^{1,b}\) = limit of detection (range) among triplicates for the RDTs; \(^{1,b}\) = quantified proportion of minority resistant variants determined by Deeplex on replicate 3.
Figure 1. Presence/absence of Xpert Ultra wild-type and mutant melt probes detected for the rifampicin-susceptible (RS):rifampicin-resistant (RR) mixtures per mutation type at various proportions of the minority resistant variants: at the limit of detection (LOD) reported as (hetero)resistant (shaded in yellow), below LOD reported as RS (shaded in pink), and at full RR reported as resistant (shaded in green).